SI3626270T1 - Zdravljenje srčno-žilnih bolezni - Google Patents

Zdravljenje srčno-žilnih bolezni

Info

Publication number: SI3626270T1
Authority: SI; Slovenia
Prior art keywords: treatment; cardiovascular diseases; cardiovascular; diseases
Prior art date: 2013-08-26

Application number

SI201432059T

Other languages

English (en)

Inventor

Victor Chengwei Shi

Martin Lefkowitz

Adel Remond Rizkala

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-26

Filing date

2014-08-26

Publication date

2024-03-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3626270(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-08-26 Priority claimed from PCT/US2013/056680 external-priority patent/WO2015030711A1/en

2014-08-26 Application filed by Novartis Ag filed Critical Novartis Ag

2024-03-29 Publication of SI3626270T1 publication Critical patent/SI3626270T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

SI201432059T 2013-08-26 2014-08-26 Zdravljenje srčno-žilnih bolezni SI3626270T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/US2013/056680 WO2015030711A1 (en)	2013-08-26	2013-08-26	New use
US201461972933P	2014-03-31	2014-03-31
EP19202854.6A EP3626270B1 (en)	2013-08-26	2014-08-26	Treatment of cardiovascular diseases

Publications (1)

Publication Number	Publication Date
SI3626270T1 true SI3626270T1 (sl)	2024-03-29

Family

ID=51494327

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201431464T SI3038654T1 (sl)	2013-08-26	2014-08-26	Nova uporaba
SI201432059T SI3626270T1 (sl)	2013-08-26	2014-08-26	Zdravljenje srčno-žilnih bolezni

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI201431464T SI3038654T1 (sl)	2013-08-26	2014-08-26	Nova uporaba

Country Status (15)

Country	Link
US (2)	US20160213646A1 (sl)
EP (3)	EP4321157B1 (sl)
JP (1)	JP6097888B2 (sl)
CY (1)	CY1122531T1 (sl)
DK (2)	DK3626270T3 (sl)
ES (2)	ES2767084T3 (sl)
FI (1)	FI3626270T3 (sl)
HR (2)	HRP20240034T1 (sl)
HU (2)	HUE064634T2 (sl)
LT (2)	LT3626270T (sl)
PL (2)	PL3626270T3 (sl)
PT (2)	PT3626270T (sl)
RS (2)	RS65037B1 (sl)
SI (2)	SI3038654T1 (sl)
WO (1)	WO2015028941A1 (sl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI3038654T1 (sl)	2013-08-26	2020-02-28	Novartis Ag	Nova uporaba
WO2016125123A1 (en) *	2015-02-06	2016-08-11	Mylan Laboratories Limited	Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
WO2016193883A1 (en) *	2015-05-29	2016-12-08	Novartis Ag	Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) *	2015-06-30	2017-01-11	深圳信立泰药业股份有限公司	一种用于心衰治疗的药物组合物及其制备方法
CN107510653A (zh) *	2016-06-17	2017-12-26	常州爱诺新睿医药技术有限公司	一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法
CN106491600A (zh) *	2015-09-06	2017-03-15	常州方楠医药技术有限公司	无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法
WO2017036420A1 (zh) *	2015-09-06	2017-03-09	常州方楠医药技术有限公司	含沙库比曲和缬沙坦的药用组合物及其制备方法
WO2017042700A1 (en) *	2015-09-07	2017-03-16	Sun Pharmaceutical Industries Limited	Solid forms of valsartan and sacubitril
WO2017063581A1 (zh) *	2015-10-16	2017-04-20	深圳信立泰药业股份有限公司	一种用于心血管疾病治疗的口服制剂及其制备方法
CN105330609B (zh) *	2015-12-07	2017-12-22	南京正大天晴制药有限公司	一种制备lcz696的方法
US20190054069A1 (en)	2016-02-03	2019-02-21	Novartis Ag	New use of a combination of sacubitril and valsartan
CN106176681A (zh) *	2016-08-25	2016-12-07	泰力特医药（湖北）有限公司	一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法
US11382866B2 (en)	2017-07-06	2022-07-12	Mankind Pharma Ltd.	Fixed dose pharmaceutical composition of valsartan and sacubitril
EP3840746A1 (en)	2018-08-23	2021-06-30	Novartis AG	New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en)	2018-08-24	2020-02-27	Novartis Ag	New drug combinations
TWI809313B (zh) *	2019-09-20	2023-07-21	大陸商深圳信立泰藥業股份有限公司	血管緊張素ii受體拮抗劑代謝產物與nep抑制劑的複合物的新心衰用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE122007000050I1 (de)	1990-02-19	2007-11-08	Novartis Ag	Acylverbindungen
US5217996A (en)	1992-01-22	1993-06-08	Ciba-Geigy Corporation	Biaryl substituted 4-amino-butyric acid amides
ES2200310T3 (es) *	1997-01-10	2004-03-01	MERCK & CO., INC.	Uso de antagonistas de la angiotensina ii losartan y exp-3174 en el tratamiento de la insuficiencia cardiaca sintomatica.
CN102091330B (zh)	2002-01-17	2015-04-08	诺华股份有限公司	含有缬沙坦和nep抑制剂的药物组合物
TW200509909A (en) *	2003-05-16	2005-03-16	Novartis Ag	Use of organic compounds
AR057882A1 (es) *	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
SI2217205T1 (sl)	2007-11-06	2015-10-30	Novartis Ag	Farmacevtske sestave na podlagi superstruktur zaviralca/blokatorja angiotenzinskih receptorjev (arb) in inhibitorja nevtralne endopeptidaze (nep)
US20100143351A1 (en)	2008-11-22	2010-06-10	Genentech, Inc.	Anti-Angiogenesis Therapy for the Treatment of Breast Cancer
CN103079554A (zh) *	2010-08-24	2013-05-01	诺华有限公司	在接受抗凝血剂疗法的哺乳动物中治疗高血压和/或预防或治疗心力衰竭
NZ704604A (en)	2012-08-24	2018-06-29	Novartis Ag	Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
SI3038654T1 (sl)	2013-08-26	2020-02-28	Novartis Ag	Nova uporaba
JP2016530282A (ja) *	2013-08-26	2016-09-29	ノバルティスアーゲー	新規使用

2014
- 2014-08-26 SI SI201431464T patent/SI3038654T1/sl unknown
- 2014-08-26 DK DK19202854.6T patent/DK3626270T3/da active
- 2014-08-26 PL PL19202854.6T patent/PL3626270T3/pl unknown
- 2014-08-26 HU HUE19202854A patent/HUE064634T2/hu unknown
- 2014-08-26 HR HRP20240034TT patent/HRP20240034T1/hr unknown
- 2014-08-26 LT LTEP19202854.6T patent/LT3626270T/lt unknown
- 2014-08-26 RS RS20240031A patent/RS65037B1/sr unknown
- 2014-08-26 PL PL14761702T patent/PL3038654T3/pl unknown
- 2014-08-26 PT PT192028546T patent/PT3626270T/pt unknown
- 2014-08-26 EP EP23202190.7A patent/EP4321157B1/en active Active
- 2014-08-26 HU HUE14761702A patent/HUE047186T2/hu unknown
- 2014-08-26 ES ES14761702T patent/ES2767084T3/es active Active
- 2014-08-26 RS RS20200047A patent/RS59816B1/sr unknown
- 2014-08-26 JP JP2016537414A patent/JP6097888B2/ja active Active
- 2014-08-26 DK DK14761702.1T patent/DK3038654T3/da active
- 2014-08-26 SI SI201432059T patent/SI3626270T1/sl unknown
- 2014-08-26 PT PT147617021T patent/PT3038654T/pt unknown
- 2014-08-26 FI FIEP19202854.6T patent/FI3626270T3/fi active
- 2014-08-26 LT LTEP14761702.1T patent/LT3038654T/lt unknown
- 2014-08-26 ES ES19202854T patent/ES2968541T3/es active Active
- 2014-08-26 WO PCT/IB2014/064074 patent/WO2015028941A1/en active Application Filing
- 2014-08-26 EP EP19202854.6A patent/EP3626270B1/en active Active
- 2014-08-26 EP EP14761702.1A patent/EP3038654B1/en active Active
- 2014-08-26 US US14/914,005 patent/US20160213646A1/en not_active Abandoned
2020
- 2020-01-16 HR HRP20200060TT patent/HRP20200060T1/hr unknown
- 2020-01-28 CY CY20201100075T patent/CY1122531T1/el unknown
- 2020-11-24 US US17/103,327 patent/US20210077461A1/en active Pending

Also Published As

Publication number	Publication date
LT3038654T (lt)	2020-01-27
JP2016528303A (ja)	2016-09-15
ES2767084T3 (es)	2020-06-16
EP3038654A1 (en)	2016-07-06
EP4321157A2 (en)	2024-02-14
FI3626270T3 (fi)	2024-01-11
JP6097888B2 (ja)	2017-03-15
US20160213646A1 (en)	2016-07-28
SI3038654T1 (sl)	2020-02-28
HRP20200060T1 (hr)	2020-04-03
PT3626270T (pt)	2024-01-11
HUE064634T2 (hu)	2024-04-28
HRP20240034T1 (hr)	2024-03-29
EP3626270B1 (en)	2023-10-11
EP3626270A1 (en)	2020-03-25
DK3626270T3 (da)	2024-01-15
PT3038654T (pt)	2020-02-04
PL3626270T3 (pl)	2024-04-08
CY1122531T1 (el)	2021-01-27
EP3038654B1 (en)	2019-10-30
EP4321157B1 (en)	2024-10-23
DK3038654T3 (da)	2020-02-03
ES2968541T3 (es)	2024-05-10
US20210077461A1 (en)	2021-03-18
PL3038654T3 (pl)	2020-05-18
RS65037B1 (sr)	2024-02-29
EP4321157A3 (en)	2024-05-15
HUE047186T2 (hu)	2020-04-28
WO2015028941A1 (en)	2015-03-05
LT3626270T (lt)	2024-01-25
RS59816B1 (sr)	2020-02-28

Publication	Publication Date	Title
IL287516A (en)	2021-12-01	Medicinal uses of empagliflozin
HRP20190101T1 (hr)	2019-03-08	Terapeutske uporabe empagliflozina
HK1219236A1 (zh)	2017-03-31	猝倒的治療
SI3626270T1 (sl)	2024-03-29	Zdravljenje srčno-žilnih bolezni
HK1213818A1 (zh)	2016-07-15	依帕列淨的治療用途
LT2981271T (lt)	2019-01-10	Empagliflozino terapinis panaudojimas
HK1220127A1 (zh)	2017-04-28	自身免疫性疾病的治療
IL241096B (en)	2021-05-31	Treatment methods
GB201403083D0 (en)	2014-04-09	Treatment of cancer
HK1232118A1 (zh)	2018-01-05	癌症的治療
GB201320014D0 (en)	2013-12-25	Treatment of cardiovascular disease
GB201321628D0 (en)	2014-01-22	Treatment of disease
GB201314303D0 (en)	2013-09-25	Treatment of HPV
GB201322347D0 (en)	2014-02-05	Treatment of cancer
GB201318742D0 (en)	2013-12-04	Treatment of cancer
GB201322778D0 (en)	2014-02-05	Method of treatment
GB201308529D0 (en)	2013-06-19	Treatment of cancer
GB201305020D0 (en)	2013-05-01	Treatment of cancer
GB201314882D0 (en)	2013-10-02	Method of treatment